AstraZeneca: In the TITANIA study, Tozorakimab 300mg reduced the risk of moderate to severe acute exacerbations by 29% in the overall COPD patient population who currently and previously smoked.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.